

SEQUENCE LISTING

<110> BIONEXIS

<120> Molecules for Targeting and releasing Therapeutic Compounds, and the use thereof

<130> 3665-165

<140> Unassigned

<141> 2005-12-07

<150> PCT/FR2004/001435

<151> 2004-06-09

<150> FR 0306944

<151> 2003-06-10

<160> 50

<170> PatentIn version 3.1

<210> 1

<211> 156

<212> PRT

<213> Homo sapiens

<400> 1

Asp Cys Arg Met Pro Met Gly Leu Ser Thr Gly Ile Ile Ser Asp Ser
1 5 10 15

Gln Ile Lys Ala Ser Glu Phe Leu Gly Tyr Trp Glu Pro Arg Leu Ala
20 25 30

Arg Leu Asn Asn Gly Gly Ser Tyr Asn Ala Trp Ser Val Glu Lys Leu
35 40 45

BEST AVAILABLE COPY

Ala Ala Glu Phe Ala Ser Lys Pro Trp Ile Gln Val Asp Met Gln Lys
50 55 60

Glu Val Ile Ile Thr Gly Ile Gln Thr Gln Gly Ala Lys His Tyr Leu
65 70 75 80

Lys Ser Cys Tyr Thr Thr Glu Phe Tyr Val Ala Tyr Ser Ser Asn Gln
85 90 95

Ile Asn Trp Gln Ile Phe Lys Gly Asn Ser Thr Arg Asn Val Met Tyr
100 105 110

Phe Asn Gly Asn Ser Asp Ala Ser Thr Ile Lys Glu Asn Gln Phe Asp
115 120 125

Pro Pro Ile Val Ala Arg Tyr Ile Arg Ile Ser Pro Thr Arg Ala Tyr
130 135 140

Asn Arg Pro Thr Leu Arg Leu Glu Leu Gln Gly Cys
145 150 155

<210> 2

<211> 156

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C1F5-S0

<400> 2

Asp Cys Arg Met Pro Leu Gly Met Ser Thr Gly Ile Ile Ser Asp Ser
1 5 10 15

Gln Ile Lys Ala Ser Glu Phe Leu Gly Tyr Trp Glu Pro Arg Leu Ala
20 25 30

Arg Leu Asn Asn Gly Gly Ser Tyr Asn Ala Trp Ser Val Glu Lys Leu
35 40 45

Ala Ala Glu Phe Ala Ser Lys Pro Trp Leu Gln Ile Asp Met Gln Lys
50 55 60

Glu Val Ile Ile Thr Gly Ile Gln Thr Gln Gly Ala Lys His Tyr Leu
65 70 75 80

Lys Ser Cys Tyr Thr Thr Glu Phe Tyr Ile Ala Tyr Ser Ser Asn Gln
85 90 95

Ile Asn Trp Gln Ile Phe Lys Gly Asn Ser Thr Arg Asn Val Met Tyr
100 105 110

Phe Asn Gly Asn Ser Asp Ala Ser Thr Ile Lys Glu Asn Gln Leu Asp
115 120 125

Pro Pro Ile Val Ala Arg Tyr Ile Arg Ile Ser Pro Thr Arg Ala Tyr
130 135 140

Asn Arg Pro Thr Leu Arg Leu Glu Leu Gln Gly Cys
145 150 155

<210> 3

<211> 156

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C1F5-S0

<400> 3

Asp Cys Arg Met Pro Met Gly Leu Ser Thr Gly Ile Ile Ser Asp Ser
1 5 10 15

Gln Ile Lys Ala Ser Glu Phe Leu Gly Tyr Trp Trp Pro Arg Leu Ala
20 25 30

Arg Leu Asn Asn Gly Gly Ser Tyr Asn Ala Trp Ser Val Glu Lys Leu
35 40 45

Ala Ala Glu Phe Ala Ser Lys Pro Trp Ile Gln Val Asp Leu Gln Lys
50 55 60

Glu Val Ile Ile Thr Gly Ile Gln Thr Gln Gly Ala Lys His Tyr Leu
65 70 75 80

Lys Ser Cys Tyr Val Thr Glu Phe Tyr Val Ala Tyr Ser Ser Asn Gln
85 90 95

Ile Asn Trp Gln Ile Phe Lys Tyr Asn Ser Thr Arg Asn Val Met Tyr
100 105 110

Phe Asn Gly Asn Ser Asp Ala Ser Thr Ile Lys Glu Asn Gln Phe Asp
115 120 125

Pro Pro Leu Val Ala Arg Tyr Ile Arg Ile Ser Pro Thr Arg Ala Tyr
130 135 140

Asn Arg Ile Thr Leu Arg Leu Glu Leu Gln Gly Cys
145 150 155

<210> 4

<211> 156

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C1F5-S0

<400> 4

Asp Cys Arg Met Pro Met Gly Leu Ser Thr Gly Ile Ile Ser Asp Ser
1 5 10 15

Gln Ile Lys Ala Ser Glu Phe Leu Gly Tyr Trp Glu Pro Arg Leu Ala
20 25 30

Arg Leu Asn Asn Gly Gly Ser Tyr Asn Ala Trp Ser Val Glu Lys Leu
35 40 45

Ala Ala Glu Phe Ala Ser Lys Pro Trp Leu Gln Ile Asp Leu Gln Lys

50

55

60

Glu Val Ile Ile Thr Gly Ile Gln Thr Gln Gly Ala Lys His Tyr Leu
65 70 75 80

Lys Ser Cys Tyr Thr Thr Glu Phe Tyr Ile Ala Tyr Ser Ser Asn Gln
85 90 95

Ile Asn Trp Gln Ile Phe Lys Gly Asn Ser Thr Arg Asn Val Met Tyr
100 105 110

Phe Asn Gly Asn Ser Asp Ala Ser Thr Ile Lys Glu Asn Gln Leu Asp
115 120 125

Pro Pro Ile Val Ala Arg Tyr Ile Arg Ile Ser Pro Thr Arg Ala Tyr
130 135 140

Asn Arg Pro Thr Leu Arg Leu Glu Leu Gln Gly Cys
145 150 155

<210> 5

<211> 150

<212> PRT

<213> homo sapiens

<400> 5

Lys Cys Gln Thr Pro Leu Gly Met Ala Ser Gly His Ile Arg Asp Phe
1 5 10 15

Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala
20 25 30

Arg Leu His Tyr Ser Gly Ser Ile Asn Ala Trp Ser Thr Lys Glu Pro
35 40 45

Phe Ser Trp Ile Lys Val Asp Leu Leu Ala Pro Met Ile Ile His Gly
50 55 60

Ile Lys Thr Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser
65 70 75 80

Gln Phe Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp Gln Thr Tyr
85 90 95

Arg Gly Asn Ser Thr Gly Thr Leu Met Val Phe Phe Gly Asn Val Asp
100 105 110

Ser Ser Gly Ile Lys His Asn Ile Phe Asn Pro Pro Ile Ile Ala Arg
115 120 125

Tyr Ile Arg Leu His Pro Thr His Tyr Ser Ile Arg Ser Thr Leu Arg
130 135 140

Met Glu Leu Met Gly Cys
145 150

<210> 6

<211> 150

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C1F8-S0

<400> 6

Lys Cys Gln Thr Pro Met Gly Leu Ala Ser Gly His Ile Arg Asp Phe
1 5 10 15

Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala
20 25 30

Arg Leu His Tyr Ser Gly Ser Ile Asn Ala Trp Ser Thr Lys Glu Pro
35 40 45

Phe Ser Trp Leu Lys Ile Asp Leu Leu Ala Pro Met Ile Ile His Gly
50 55 60

Ile Lys Thr Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser
65 70 75 80

Gln Tyr Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp Gln Thr Tyr
85 90 95

Arg Gly Asn Ser Thr Gly Thr Leu Met Val Phe Phe Gly Asn Val Asp
100 105 110

Ser Ser Gly Ile Lys His Asn Ile Phe Asn Pro Pro Ile Ile Ala Arg
115 120 125

Tyr Ile Arg Leu His Pro Thr His Tyr Ser Ile Arg Ser Thr Leu Arg
130 135 140

Met Glu Leu Met Gly Cys
145 150

<210> 7

<211> 150

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C1F8-S0

<400> 7

Lys Cys Gln Thr Pro Met Gly Leu Ala Ser Gly His Ile Arg Asp Phe
1 5 10 15

Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala
20 25 30

Arg Leu His Tyr Ser Gly Ser Ile Asn Ala Trp Ser Thr Lys Glu Pro
35 40 45

Phe Ser Trp Ile Lys Val Asp Leu Leu Ala Pro Met Ile Ile His Gly
50 55 60

Val Lys Thr Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser
65 70 75 80

Gln Phe Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp Gln Thr Tyr
85 90 95

Arg Tyr Asn Ser Thr Gly Thr Leu Met Val Phe Phe Gly Asn Val Asp
100 105 110

Ser Ser Gly Ile Lys His Asn Ile Phe Asn Pro Pro Leu Ile Ala Arg
115 120 125

Tyr Ile Arg Leu His Pro Thr His Tyr Ser Ile Arg Ser Thr Leu Arg
130 135 140

Met Glu Leu Met Gly Cys
145 150

<210> 8

<211> 150

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C1F8-S0

<400> 8

Lys Cys Gln Thr Pro Leu Gly Met Ala Ser Gly His Ile Arg Asp Phe
1 5 10 15

Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp Trp Pro Lys Leu Ala
20 25 30

Arg Leu His Tyr Ser Gly Ser Ile Asn Ala Trp Ser Thr Lys Glu Pro
35 40 45

Phe Ser Trp Leu Lys Ile Asp Leu Leu Ala Pro Met Ile Ile His Gly
50 55 60

Ile Lys Thr Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser
65 70 75 80

Gln Phe Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp Gln Thr Tyr
85 90 95

Arg Gly Asn Ser Thr Gly Thr Leu Met Val Phe Phe Gly Asn Val Asp
100 105 110

Ser Ser Gly Ile Lys His Asn Ile Phe Asn Pro Pro Leu Leu Ala Arg
115 120 125

Tyr Ile Arg Leu His Pro Thr His Tyr Ser Ile Arg Ser Thr Leu Arg
130 135 140

Met Glu Val Met Gly Cys
145 150

<210> 9

<211> 159

<212> PRT

<213> homo sapiens

<400> 9

Cys Ser Thr Pro Leu Gly Met Glu Asn Gly Lys Ile Glu Asn Lys Gln
1 5 10 15

Ile Thr Ala Ser Ser Phe Lys Lys Ser Trp Trp Gly Asp Tyr Trp Glu
20 25 30

Pro Phe Arg Ala Arg Leu Asn Ala Gln Gly Arg Val Asn Ala Trp Gln
35 40 45

Ala Lys Ala Asn Asn Asn Lys Gln Trp Leu Glu Ile Asp Leu Leu Lys
50 55 60

Ile Lys Lys Ile Thr Ala Ile Ile Thr Gln Gly Cys Lys Ser Leu Ser
65 70 75 80

Ser Glu Met Tyr Val Lys Ser Tyr Thr Ile His Tyr Ser Glu Gln Gly
85 90 95

Val Glu Trp Lys Pro Tyr Arg Leu Lys Ser Ser Met Val Asp Lys Ile

100

105

110

Phe Glu Gly Asn Thr Asn Thr Lys Gly His Val Lys Asn Phe Phe Asn
 115 120 125

Pro Pro Ile Ile Ser Arg Phe Ile Arg Val Ile Pro Lys Thr Trp Asn
 130 135 140

Gln Ser Ile Thr Leu Arg Leu Glu Leu Phe Gly Cys Asp Ile Tyr
 145 150 155

<210> 10

<211> 159

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C2F5-S0

<400> 10

Cys Ser Thr Pro Leu Gly Met Glu Asn Gly Lys Ile Glu Asn Lys Gln
 1 5 10 15

Ile Thr Ala Ser Ser Phe Lys Lys Ser Trp Trp Gly Asp Tyr Trp Glu
 20 25 30

Pro Phe Arg Ala Arg Leu Asn Ala Gln Gly Arg Val Asn Ala Trp Gln
 35 40 45

Pro Lys Ala Asn Asn Asn Lys Gln Trp Leu Glu Val Asp Leu Leu Lys
 50 55 60

Ile Lys Lys Ile Thr Ala Val Ile Thr Gln Gly Cys Lys Ser Leu Ser
 65 70 75 80

Ser Glu Met Tyr Val Lys Ser Phe Thr Ile His Tyr Ser Glu Gln Gly
 85 90 95

Val Glu Trp Lys Pro Phe Arg Leu Lys Ser Ser Met Val Asp Lys Ile
 100 105 110

Asn Glu Gly Asn Thr Asn Thr Lys Gly His Val Lys Asn Phe Pro Asn
115 120 125

Pro Pro Arg Ile Ser Arg Phe Ile Arg Val Ile Pro Lys Thr Trp Asn
130 135 140

Gln Ser Ile Thr Leu Arg Leu Glu Leu Phe Gly Cys Asp Ile Tyr
145 150 155

<210> 11

<211> 159

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C2F5-S0

<400> 11

Cys Ser Thr Pro Leu Gly Ile Glu Asn Gly Lys Ile Glu Asn Lys Gln
1 5 10 15

Ile Thr Ala Ser Ser Phe Lys Lys Ser Trp Trp Gly Asp Tyr Trp Glu
20 25 30

Pro Phe Arg Ala Arg Leu Asn Ala Gln Gly Arg Val Asn Ala Trp Gln
35 40 45

Ala Lys Ala Asn Asn Asn Lys Gln Trp Leu Glu Met Asp Phe Leu Lys
50 55 60

Ile Lys Lys Val Thr Ala Val Ile Thr Gln Gly Cys Lys Ser Leu Ser
65 70 75 80

Ser Glu Met Tyr Val Lys Ser Phe Thr Ile His Tyr Ser Glu Gln Gly
85 90 95

Val Glu Trp Lys Pro Tyr Arg Leu Lys Ser Ser Met Val Asp Lys Ile
100 105 110

Phe Glu Gly Asn Thr Asn Thr Lys Gly His Val Lys Asn Phe Phe Asn
115 120 125

Pro Pro Ile Ile Ser Arg Phe Ile Arg Gln Ile Pro Lys Thr Trp Asn
130 135 140

Gln Ser Ile Thr Leu Arg Leu Glu Leu Tyr Gly Cys Asp Ile Tyr
145 150 155

<210> 12

<211> 159

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C2F5-S0

<400> 12

Cys Ser Thr Pro Leu Gly Ile Glu Asn Gly Lys Ile Glu Asn Lys Gln
1 5 10 15

Ile Thr Ala Ser Ser Phe Lys Lys Ser Trp Trp Gly Asp Tyr Trp Glu
20 25 30

Pro Phe Arg Leu Arg Leu Asn Ala Gln Gly Arg Val Asn Ala Trp Gln
35 40 45

Ala Lys Ala Asn Asn Asn Lys Gln Trp Ala Glu Met Asp Leu Leu Lys
50 55 60

Ile Lys Lys Ile Thr Ala Ile Ile Thr Gln Gly Cys Lys Ser Leu Ser
65 70 75 80

Ser Glu Met Tyr Val Lys Ser Tyr Thr Ile His Tyr Ser Glu Gln Gly
85 90 95

Val Glu Trp Lys Pro Tyr Arg Leu Lys Ser Ser Met Val Asp Lys Ile
100 105 110

Phe Glu Gly Asn Thr Asn Thr Lys Gly His Val Lys Asn Phe Phe Asn
 115 120 125

Pro Pro Ile Ile Thr Arg Phe Ile Arg Val Ile Pro Lys Thr Trp Asn
 130 135 140

Gln Ser Ile Thr Ile Arg Leu Glu Leu Phe Gly Cys Asp Ile Tyr
 145 150 155

<210> 13

<211> 153

<212> PRT

<213> homo sapiens

<400> 13

Cys Ser Met Pro Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln
 1 5 10 15

Ile Thr Ala Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser Pro
 20 25 30

Ser Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp Arg Pro
 35 40 45

Gln Val Asn Asn Pro Lys Glu Trp Leu Gln Val Asp Phe Gln Lys Thr
 50 55 60

Met Lys Val Thr Gly Val Thr Thr Gln Gly Val Lys Ser Leu Leu Thr
 65 70 75 80

Ser Met Tyr Val Lys Glu Phe Leu Ile Ser Ser Ser Gln Asp Gly His
 85 90 95

Gln Trp Thr Leu Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly
 100 105 110

Asn Gln Asp Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Pro Leu
 115 120 125

Leu Thr Arg Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln Ile

130

135

140

Ala Leu Arg Met Glu Val Leu Gly Cys
 145 150

<210> 14

<211> 153

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C2F8-S0

<400> 14

Cys Ser Met Pro Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln
 1 5 10 15

Ile Thr Ala Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser Pro
 20 25 30

Ser Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp Arg Ala
 35 40 45

Gln Val Asn Asn Pro Lys Glu Trp Leu Gln Ile Asp Leu Gln Lys Thr
 50 55 60

Met Lys Ile Thr Gly Ile Thr Thr Gln Gly Val Lys Ser Leu Leu Thr
 65 70 75 80

Ser Met Tyr Val Lys Glu Tyr Leu Ile Ser Ser Ser Gln Asp Gly His
 85 90 95

Gln Trp Thr Leu Phe Tyr Gln Asn Gly Lys Val Lys Val Phe Gln Gly
 100 105 110

Asn Gln Asp Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Phe Leu
 115 120 125

Leu Thr Arg Tyr Leu Arg Ile His Pro Val Ser Trp Val His Gln Ile
 130 135 140

Ala Leu Arg Met Glu Val Leu Gly Cys
145 150

<210> 15

<211> 153

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C2F8-S0

<400> 15

Cys Ser Met Pro Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln
1 5 10 15

Ile Thr Ala Ser Ser Tyr Lys Thr Asn Met Phe Ala Thr Trp Ser Pro
20 25 30

Ser Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp Arg Ala
35 40 45

Gln Val Asn Asn Pro Lys Gln Trp Leu Gln Val Asp Phe Gln Lys Thr
50 55 60

Met Lys Val Thr Gly Val Thr Thr Gln Gly Val Lys Ser Leu Leu Thr
65 70 75 80

Ser Met Tyr Val Lys Glu Phe Leu Ile Ser Ser Ser Gln Asp Gly His
85 90 95

Gln Trp Thr Leu Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly
100 105 110

Phe Gln Asp Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Pro Leu
115 120 125

Leu Thr Ile Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln Ile
130 135 140

Ala Leu Arg Met Glu Val Leu Glu Cys
145 150

<210> 16

<211> 153

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide built on the basis of C2F8-S0

<400> 16

Cys Ser Met Pro Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln
1 5 10 15

Ile Thr Ala Ser Ser Tyr Lys Thr Asn Met Phe Ala Thr Trp Ser Pro
20 25 30

Ser Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp Arg Pro
35 40 45

Gln Val Asn Asn Pro Lys Glu Trp Leu Gln Val Asp Phe Gln Lys Thr
50 55 60

Met Lys Val Thr Gly Val Thr Thr Gln Gly Val Lys Ser Leu Leu Thr
65 70 75 80

Ser Met Tyr Val Lys Glu Tyr Leu Ile Ser Ser Ser Gln Asp Gly His
85 90 95

Gln Trp Thr Leu Phe Tyr Gln Asn Gly Lys Val Lys Val Phe Gln Gly
100 105 110

Asn Gln Asp Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Phe Leu
115 120 125

Leu Thr Arg Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln Ile
130 135 140

Ala Leu Arg Met Glu Val Leu Glu Cys
145 150

<210> 17

<211> 86

<212> PRT

<213> homo sapiens

<400> 17

Thr Lys Ala Ser Cys Lys Val Pro Val Lys Lys Ala Thr Val Val Tyr
1 5 10 15

Gln Gly Glu Arg Val Lys Ile Gln Glu Lys Phe Lys Asn Gly Met Leu
20 25 30

His Gly Asp Lys Val Ser Phe Phe Cys Lys Asn Lys Glu Lys Lys Cys
35 40 45

Ser Tyr Thr Glu Asp Ala Gln Cys Ile Asp Gly Thr Ile Glu Val Pro
50 55 60

Lys Cys Phe Lys Glu His Ser Ser Leu Ala Phe Trp Lys Thr Asp Ala
65 70 75 80

Ser Asp Val Lys Pro Cys
85

<210> 18

<211> 86

<212> PRT

<213> homo sapiens

<220>

<221> MISC_FEATURE

<222> (2) .. (2)

<223> Xaa is Lys, Asp, or Glu

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is Tyr or Phe

<220>

<221> MISC_FEATURE

<222> (17)..(17)

<223> Xaa is Glu or Gln

<220>

<221> MISC_FEATURE

<222> (22)..(22)

<223> Xaa is Lys or Arg

<220>

<221> MISC_FEATURE

<222> (28)..(28)

<223> Xaa is Lys, or Arg

<220>

<221> MISC_FEATURE

<222> (42)..(42)

<223> Xaa is Lys, or Arg

<220>

<221> MISC_FEATURE
<222> (44)..(44)
<223> Xaa is Lys, or Arg

<220>

<221> MISC_FEATURE
<222> (46)..(46)
<223> Xaa is Lys, or Arg

<220>

<221> MISC_FEATURE
<222> (47)..(47)
<223> Xaa is Lys, or Arg

<220>

<221> MISC_FEATURE
<222> (68)..(68)
<223> Xaa is Lys, or Arg

<220>

<221> MISC_FEATURE
<222> (77)..(77)
<223> Xaa is Lys, or Arg

<220>

<221> MISC_FEATURE
<222> (84)..(84)
<223> Xaa is Lys, or Arg

<220>

<221> MISC_FEATURE

<222> (49) .. (49)

<223> Xaa is Ser or Thr

<220>

<221> MISC_FEATURE

<222> (72) .. (72)

<223> Xaa is Ser, Thr or Met

<220>

<221> MISC_FEATURE

<222> (7) .. (7)

<223> Xaa is Leu, Val or Ile

<220>

<221> MISC_FEATURE

<222> (12) .. (12)

<223> Xaa is Ala or Met

<220>

<221> MISC_FEATURE

<222> (14) .. (14)

<223> Xaa is Val, Ile, or Thr

<220>

<221> MISC_FEATURE

<222> (15) .. (15)

<223> Xaa is Val, Ile, or Thr

<220>

<221> MISC_FEATURE

<222> (21)..(21)

<223> Xaa is Val, Ile, or Thr

<220>

<221> MISC_FEATURE

<222> (23)..(23)

<223> Xaa is Val, Ile, or Thr

<220>

<221> MISC_FEATURE

<222> (37)..(37)

<223> Xaa is Val, Ile, or Thr

<220>

<221> MISC_FEATURE

<222> (27)..(27)

<223> Xaa is Phe or Tyr

<220>

<221> MISC_FEATURE

<222> (40)..(40)

<223> Xaa is Phe or Tyr

<220>

<221> MISC_FEATURE

<222> (54)..(54)

<223> Xaa is Ala, Val or Ile

<220>

<221> MISC_FEATURE

<222> (61)..(61)

<223> Xaa is Ile, Val, or Met

<220>

<221> MISC_FEATURE

<222> (67)..(67)

<223> Xaa is Phe or Tyr

<220>

<221> MISC_FEATURE

<222> (73)..(73)

<223> Xaa is Leu, Ile, Phe, Tyr, Met, or Trp

<220>

<221> MISC_FEATURE

<222> (74)..(74)

<223> Xaa is Leu, Ile, Phe, Tyr, Met, or Trp

<220>

<221> MISC_FEATURE

<222> (75)..(75)

<223> Xaa is Leu, Ile, Phe, Tyr, Met, or Trp

<220>

<221> MISC_FEATURE

<222> (76)..(76)

<223> Xaa is Leu, Ile, Phe, Tyr, Met, or Trp

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> Xaa is Val, Ile or Thr

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> Xaa is Lys, or Arg

<400> 18

Thr	Xaa	Ala	Ser	Cys	Lys	Xaa	Pro	Xaa	Lys	Xaa	Xaa	Thr	Xaa	Xaa	Xaa
1				5					10					15	

Xaa	Gly	Glu	Arg	Xaa	Xaa	Xaa	Gln	Glu	Lys	Xaa	Xaa	Asn	Gly	Met	Leu
			20					25					30		

His	Gly	Asp	Lys	Xaa	Ser	Phe	Xaa	Cys	Xaa	Asn	Xaa	Glu	Xaa	Xaa	Cys
		35					40					45			

Xaa	Tyr	Thr	Glu	Asp	Xaa	Gln	Cys	Ile	Asp	Gly	Thr	Xaa	Glu	Val	Pro
	50					55					60				

Lys	Cys	Xaa	Xaa	Glu	His	Ser	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Thr	Asp	Ala
65					70				75						80

Ser	Asp	Val	Xaa	Pro	Cys
					85

<210> 19

<211> 86

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide derived from domain 5 of beta2glycoprotein I

<400> 19

Thr Glu Ala Ser Cys Lys Val Pro Val Lys Arg Ala Thr Val Val Tyr
1 5 10 15

Glu Gly Glu Arg Val Arg Ile Gln Glu Lys Phe Lys Asn Gly Met Leu
20 25 30

His Gly Asp Lys Val Ser Phe Phe Cys Arg Asn Arg Glu Arg Arg Cys
35 40 45

Ser Tyr Thr Glu Asp Ala Gln Cys Ile Asp Gly Thr Ile Glu Val Pro
50 55 60

Lys Cys Tyr Arg Glu His Ser Met Leu Thr Trp Trp Arg Thr Asp Ala
65 70 75 80

Ser Asp Val Lys Pro Cys
85

<210> 20

<211> 86

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide derived from domain 5 of beta2glycoprotein I

<400> 20

Thr Glu Ala Ser Cys Lys Leu Pro Thr Lys Arg Met Thr Val Val Tyr

Ser Asp Val Lys Pro Cys
85

<210> 22

<211> 86

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide derived from domain 5 of beta2glycoprotein I

<400> 22

Thr Lys Ala Ser Cys Lys Val Pro Thr Lys Lys Met Thr Val Val Tyr
1 5 10 15

Gln Gly Glu Arg Val Lys Ile Gln Glu Lys Phe Lys Asn Gly Met Leu
20 25 30

His Gly Asp Lys Ile Ser Phe Phe Cys Lys Asn Lys Glu Lys Lys Cys
35 40 45

Ser Tyr Thr Glu Asp Ala Gln Cys Ile Asp Gly Thr Ile Glu Val Pro
50 55 60

Lys Cys Tyr Lys Glu His Ser Ser Leu Ala Phe Trp Lys Thr Asp Ala
65 70 75 80

Ser Asp Val Lys Pro Cys
85

<210> 23

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 23

Gly Phe Asp Glu Arg Ala Asp Val Glu Thr Leu Arg Lys Ala Met Lys
1 5 10 15

Gly Leu Gly Thr Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg
20 25 30

Ser Asn Ala Gln Arg Gln Glu Ile Ser Ala Ala Tyr Lys Thr Leu Phe
35 40 45

Gly Arg Asp Leu Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe
50 55 60

Glu Lys Leu Val Val Ala Leu Leu Lys Pro Ser
65 70 75

<210> 24

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 24

Asn Phe Asp Ala Glu Arg Asp Ala Leu Asn Ile Arg Lys Ala Ile Lys
1 5 10 15

Gly Met Gly Thr Asp Glu Asp Thr Ile Val Gln Ile Leu Thr Asn Arg
20 25 30

Ser Asn Ala Gln Arg Gln Asp Ile Ala Phe Ala Tyr Gln Arg Arg Thr
35 40 45

Lys Arg Glu Leu Ala Ser Asp Leu Lys Ser Glu Leu Ser Gly His Leu
50 55 60

Glu Arg Val Ile Leu Gly Leu Leu Lys Thr Ser
65 70 75

<210> 25

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 25

Asp Phe Ser Pro Ser Val Asp Ala Glu Ala Ile Arg Lys Ala Ile Lys
1 5 10 15

Gly Ile Gly Thr Asp Glu Asp Met Leu Ile Ser Ile Leu Thr Glu Arg
20 25 30

Ser Asn Ala Gln Arg Gln Leu Ile Val Lys Glu Tyr Gln Ala Ala Tyr
35 40 45

Gly Arg Glu Leu Lys Asp Asp Leu Lys Ser Glu Leu Ser Gly His Phe
50 55 60

Glu Arg Leu Met Val Ala Leu Val Thr Pro Ser
65 70 75

<210> 26

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 26

Gly Phe Asn Ala Met Glu Asp Val Gln Thr Leu Arg Lys Ala Met Lys

1 5 10 15
 Gly Leu Gly Thr Asp Glu Asp Ala Leu Ile Ser Val Leu Ala Tyr Arg
 20 25 30
 Asn Thr Ala Gln Arg Gln Glu Ile Arg Thr Ala Tyr Arg Ser Thr Ile
 35 40 45
 Gly Arg Asp Leu Ile Asp Asp Leu Lys Ser Glu Leu Ser Gly Asn Phe
 50 55 60
 Glu Arg Val Ile Val Gly Met Leu Thr Pro Ser
 65 70 75

<210> 27

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 27

Gly Phe Asp Pro Asn Gln Asp Ala Glu Thr Leu Arg Thr Ala Met Lys
 1 5 10 15
 Gly Phe Gly Thr Asp Glu Glu Ala Ile Leu Asp Ile Ile Thr Ser Arg
 20 25 30
 Ser Asn Arg Gln Arg Gln Glu Val Ser Gln Ser Tyr Lys Ser Leu Tyr
 35 40 45
 Gly Arg Asp Leu Ile Ala Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe
 50 55 60
 Glu Arg Leu Ile Val Gly Leu Met Arg Pro Ser
 65 70 75

<210> 28

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 28

Gly Phe Asn Pro Asp Gln Asp Ala Gln Ala Leu Arg Lys Ala Met Lys
1 5 10 15

Gly Leu Gly Thr Asp Glu Asp Thr Ile Ile Asp Ile Ile Ala His Arg
20 25 30

Ser Asn Val Gln Arg Gln Glu Ile Arg Gln Ala Phe Lys Ser His Phe
35 40 45

Gly Arg Glu Leu Met Thr Asp Leu Lys Ser Glu Ile Ser Gly Asp Leu
50 55 60

Glu Arg Leu Ile Leu Gly Leu Met Met Pro Ser
65 70 75

<210> 29

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 29

Pro Gly Asp Ala Ile Lys Asp Val Glu Ile Leu Arg Lys Ala Met Lys
1 5 10 15

Gly Phe Gly Thr Asp Glu Asp Ala Ile Val Asp Ile Val Ala Asn Arg
20 25 30

Ser Asn Asp Gln Arg Gln Lys Ile Lys Ala Ala Phe Lys Thr Ser Tyr
35 40 45

Gly Arg Asp Leu Ile Lys Asp Leu Lys Ser Glu Leu Ser Gly Asn Leu
50 55 60

Glu Arg Leu Ile Leu Ala Leu Phe Met Pro Ser
65 70 75

<210> 30

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 30

His Phe Asn Pro Asp Pro Asp Val Ala Ala Leu Arg Lys Ala Met Lys
1 5 10 15

Gly Ile Gly Thr Asp Glu Asp Ala Ile Ile Asp Ile Leu Thr Ser Arg
20 25 30

Ser Asn Thr Gln Arg Gln Glu Ile Ala Glu Ser Phe Lys Ala Gln Phe
35 40 45

Gly Arg Asp Leu Thr Glu Asp Leu Lys Ser Glu Leu Ser Gly Lys Leu
50 55 60

Glu Arg Leu Ile Val Ala Leu Met Tyr Pro Ser
65 70 75

<210> 31

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 31

Gly Phe Asp Pro Leu Arg Asp Ala Glu Ala Leu Arg Lys Ala Met Lys
1 5 10 15

Gly Phe Gly Thr Asp Glu Asp Ala Ile Ile Asp Leu Leu Gly Ser Arg
20 25 30

Ser Asn Lys Gln Arg Gln Gln Ile Leu Leu Ser Phe Lys Thr Ala Tyr
35 40 45

Gly Arg Asp Leu Ile Lys Asp Leu Lys Ser Glu Leu Ser Gly Asn Phe
50 55 60

Glu Arg Thr Ile Leu Ala Leu Met Lys Thr Ser
65 70 75

<210> 32

<211> 75

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence derived from a human annexine

<400> 32

Gly Phe Asp Val Asp Arg Asp Ala Lys Ala Leu Arg Lys Ala Met Lys
1 5 10 15

Gly Met Gly Thr Asp Glu Asp Ala Ile Ile Glu Ile Leu Thr Ser Arg
20 25 30

Thr Ser Asp Glu Arg Gln Glu Ile Lys Gln Lys Tyr Lys Ala Thr Tyr
35 40 45

Gly Arg Glu Leu Glu Glu Asp Leu Lys Ser Glu Leu Ser Gly Asn Phe

50

55

60

Glu Lys Val Ala Leu Ala Leu Leu Asp Thr Ser
65 70 75

<210> 33

<211> 31

<212> PRT

<213> homo sapiens

<400> 33

Ala Met Val Ser Glu Phe Leu Lys Gln Ala Trp Phe Ile Glu Asn Glu
1 5 10 15

Glu Gln Glu Tyr Val Gln Thr Val Lys Ser Ser Lys Gly Gly Pro
20 25 30

<210> 34

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide derived from the segment N-terminal of the annexine I

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa is Leu or Ile

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> Xaa is Lys or Asn

<220>

<221> MISC_FEATURE

<222> (11) .. (11)

<223> Xaa is Trp, Tyr or Cys

<220>

<221> MISC_FEATURE

<222> (12) .. (12)

<223> Xaa is Tyr or Phe

<220>

<221> MISC_FEATURE

<222> (13) .. (13)

<223> Xaa is Ile, Leu or Met

<220>

<221> MISC_FEATURE

<222> (14) .. (14)

<223> Xaa is Asp or Glu

<220>

<221> MISC_FEATURE

<222> (16) .. (16)

<223> Xaa is Glu, Gln, or Leu

<220>

<221> MISC_FEATURE

<222> (19)..(19)

<223> Xaa is Glu, or Asp

<220>

<221> MISC_FEATURE

<222> (20)..(20)

<223> Xaa is Tyr or Cys

<220>

<221> MISC_FEATURE

<222> (21)..(21)

<223> Xaa is Val or Ile

<220>

<221> MISC_FEATURE

<222> (22)..(22)

<223> Xaa is Gln, Lys, Asn, or Glu

<220>

<221> MISC_FEATURE

<222> (23)..(23)

<223> Xaa is Thr, Ser, Cys, Ala

<220>

<221> MISC_FEATURE

<222> (24)..(24)

<223> Xaa is Val Thr or Ser

<220>

<221> MISC_FEATURE

<222> (25) .. (25)

<223> Xaa is Lys or Gln

<220>

<221> MISC_FEATURE

<222> (26) .. (26)

<223> Xaa is Ser, Thr, Cys, or Gly

<220>

<221> MISC_FEATURE

<222> (27) .. (27)

<223> Xaa is Ser, Tyr, Val, Gly

<220>

<221> MISC_FEATURE

<222> (28) .. (28)

<223> Xaa is Lys, His, Ser, or Pro

<220>

<221> MISC_FEATURE

<222> (29) .. (29)

<223> Xaa is Gly or Val

<220>

<221> MISC_FEATURE

<222> (30) .. (30)

<223> Xaa is Gly or Val

<400> 34

Ala Met Val Ser Glu Phe Xaa Xaa Gln Ala Xaa Xaa Xaa Xaa Asn Xaa
1 5 10 15

Glu Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro
20 25 30

<210> 35

<211> 18

<212> PRT

<213> homo sapiens

<400> 35

Glu Asn Glu Glu Gln Glu Tyr Val Gln Thr Val Lys Ser Ser Lys Gly
1 5 10 15

Gly Pro

<210> 36

<211> 62

<212> PRT

<213> Artificial Sequence

<220>

<223> inhibitor of TNFR1 derived from CRD1

<400> 36

Asp Ser Val Cys Pro Gln Gly Lys Tyr Ile His Pro Gln Asn Asn Ser
1 5 10 15

Ile Cys Cys Thr Lys Cys His Lys Gly Thr Tyr Leu Tyr Asn Asp Cys
20 25 30

Pro Gly Pro Gly Gln Asp Thr Asp Cys Arg Glu Cys Glu Ser Gly Ser
35 40 45

Phe Thr Ala Ser Glu Asn His Leu Arg His Cys Leu Ser Ser
50 55 60

<210> 37

<211> 60

<212> PRT

<213> Artificial Sequence

<220>

<223> inhibitor of TNFR2 derived from CRD1

<400> 37

Pro Gly Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met
1 5 10 15

Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys Val Phe Cys Thr
20 25 30

Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr
35 40 45

Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Ser
50 55 60

<210> 38

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> cleavable bond

<220>

<221> SITE

<222> (6)..(7)

<223> Site of cleavage

<400> 38

Ser Pro Leu Ala Gln Ala Val Arg Ser Ser Ser Arg
1 5 10

<210> 39

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> cleavable bond

<220>

<221> SITE

<222> (5)..(6)

<223> site of cleavage

<400> 39

Pro Leu Ala Gln Ala Val Arg Ser Ser Ser
1 5 10

<210> 40

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> cleavable bond

<220>

<221> SITE

<222> (4)..(5)

<223> site of cleavage

<400> 40

Leu Ala Gln Ala Val Arg Ser Ser
1 5

<210> 41

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> cleavable bond

<220>

<221> SITE

<222> (3)..(4)

<223> site of cleavage

<400> 41

Ala Gln Ala Val Arg Ser
1 5

<210> 42

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> cleavable bond

<220>

<221> SITE

<222> (2)..(3)

<223> site of cleavage

<400> 42

Gln Ala Val Arg
1

<210> 43

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> cleavable bond

<220>

<221> SITE

<222> (5)..(6)

<223> site of cleavage

<400> 43

Pro Leu Ala Gln Ala Val Arg Ser
1 5

<210> 44

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> cleavable bond

<220>

<221> SITE

<222> (3)..(4)

<223> site of cleavage

<400> 44

Ala Gln Ala Val Arg Ser Ser
1 5

<210> 45

<211> 56

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide NTA1c+

<400> 45

cgaaaacgaa gaacaggaat acgttcagac cgtaaatact tctaaagggtg gtccgg

56

<210> 46

<211> 64

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide NTA1c-

<400> 46

gatcccgac cacctttaga agatttaacg gtctgaacgt attcctgttc ttcgttttgc 60

ggcc 64

<210> 47

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide NTA11+

<400> 47

cgctatgggt tctgaattcc tgaaacaggc ttggttcac gaaaacgaag aacaggaata 60

cgttcagacc gttaaattct ctaaagggtg tccgg 95

<210> 48

<211> 103

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide NTA11-

<400> 48

gatcccgac cacctttaga agatttaacg gtctgaacgt attcctgttc ttcgttttgc 60

atgaaccaag cctgtttcag gaattcagaa accatagcgg gcc 103

<210> 49

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide Ban II +

<400> 49
gcgctgtag cgggtccatt aagttctgtc

30

<210> 50

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide Ban II -

<400> 50
gacagaactt aatggaccgc ctaacagcgc

30

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.